Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has appointed William E. Gannon Jr., MD, MBA, as vice president of Regulatory Affairs. With more than three decades of experience in the biotech and pharmaceutical industries and an impressive background in oncology and gene therapy, Gannon brings invaluable expertise in the areas of clinical development, regulatory affairs and commercialization of products. He is currently chief scientific officer and medical director at Capital City Technical Consulting, where he has directed clinical trial development and operations management for clients in both the biotech and pharmaceutical industries. In his new role at Genprex, Gannon will oversee the company’s clinical trials, including those that combine Genprex’s lead drug candidate, GPX-001 for non-small cell lung cancer (“NSCLC”), with AstraZeneca’s targeted therapy Tagrisso(R) and with immunotherapy Keytruda(R). “We are pleased to have Dr. Gannon join our team,” said Genprex chairman and CEO Rodney Varner in the press release. “His extensive experience in the management of clinical trials, from designing trials to building operational teams, will be an important asset for us as we work toward initiating our upcoming trials and seeing them through to successful completion.”
To view the full press release, visit http://ibn.fm/3TQFj
About Genprex Inc.
Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
